

Disrupted Excitation-Inhibition Balance in Cognitively Normal Individuals at Risk of Alzheimer's Disease

Igor Fortel^a, Liang Zhan^b, Olusola Ajilore^c, Yichao Wu^d, Scott Mackin^e and Alex Leow^{a,c,*}

^aDepartment of Biomedical Engineering, University of Illinois at Chicago, Chicago, IL, USA

^bDepartment of Electrical and Computer Engineering, University of Pittsburgh, Pittsburgh, PA, USA

^cDepartment of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA

^dDepartment of Math, Statistics and Computer Science, University of Illinois at Chicago, Chicago, IL, USA

^eDepartment of Psychiatry, University of California – San Francisco, San Francisco, CA, USA

Accepted 24 July 2023

Pre-press 11 September 2023

Abstract.

Background: Sex differences impact Alzheimer's disease (AD) neuropathology, but cell-to-network level dysfunctions in the prodromal phase are unclear. Alterations in hippocampal excitation-inhibition balance (EIB) have recently been linked to early AD pathology.

Objective: Examine how AD risk factors (age, *APOE* $\epsilon 4$, amyloid- β) relate to hippocampal EIB in cognitively normal males and females using connectome-level measures.

Methods: Individuals from the OASIS-3 cohort (age 42–95) were studied ($N = 437$), with a subset aged 65+ undergoing neuropsychological testing ($N = 231$).

Results: In absence of AD risk factors (*APOE* $\epsilon 4/\text{A}\beta+$), whole-brain EIB decreases with age more significantly in males than females ($p = 0.021$, $\beta = -0.007$). Regression modeling including *APOE* $\epsilon 4$ allele carriers ($\text{A}\beta-$) yielded a significant positive AGE-by-*APOE* interaction in the right hippocampus for females only ($p = 0.013$, $\beta = 0.014$), persisting with inclusion of $\text{A}\beta+$ individuals ($p = 0.012$, $\beta = 0.014$). Partial correlation analyses of neuropsychological testing showed significant associations with EIB in females: positive correlations between right hippocampal EIB with categorical fluency and whole-brain EIB with the Trail Making Test ($p < 0.05$).

Conclusions: Sex differences in EIB emerge during normal aging and progresses differently with AD risk. Results suggest *APOE* $\epsilon 4$ disrupts hippocampal balance more than amyloid in females. Increased excitation correlates positively with neuropsychological performance in the female group, suggesting a duality in terms of potential beneficial effects prior to cognitive impairment. This underscores the translational relevance of *APOE* $\epsilon 4$ related hyperexcitation in females, potentially informing therapeutic targets or early interventions to mitigate AD progression in this vulnerable population.

Keywords: Alzheimer's disease, amyloid- β , apolipoprotein E, brain dynamics, hyperexcitation, excitation-inhibition balance

*Correspondence to: Alex Leow MD, PhD, School of Public Health/Psychiatric Institute (SPHPI), 1601W. Taylor St., SPHPI MC 912, Chicago, IL 60612, USA. Tel.: +1 626 757 8704; E-mail: alexleow@alumni.ucla.edu.

INTRODUCTION

With networks composed of billions of neurons and synaptic connections, the human brain is a highly complex dynamical system wherein neural populations coordinate electrical activity to balance excitatory and inhibitory neural activity across different brain regions. Balanced excitation and inhibition is crucial for adjusting neural input/output relationships in cortical networks, regulating their dynamic range of responses to stimuli [1], and achieving optimal information capacity and transfer [2]. Moreover, maintaining this balance is essential for healthy cerebral activity, homeostatic control, and potentially contributing to lifespan longevity [3–5]. Imbalances, however, may lead to serious neurological disorders such as autism, characterized by a shift towards a more excitatory state [6, 7], and Down syndrome, linked to increased inhibition (or decreased excitation) [8].

Growing evidence supports the hypothesis that neuronal hyperexcitation, due to the susceptibility of inhibitory GABAergic interneurons to Apolipoprotein (*APOE*) $\epsilon 4$ -mediated neurotoxicity (particularly in the hippocampal dentate gyrus), may represent the earliest changes indicative of Alzheimer's disease (AD) pathology [9–11]. Normal age-related declines in excitatory connectivity may result from alterations in synaptic plasticity, receptor expression, and neuronal morphology, leading to changes in excitatory and inhibitory signaling [9–11]. Here, we leverage a recently developed framework based on a pairwise maximum entropy model from statistical physics to computationally infer excitation-inhibition balance (EIB) from combined structural and functional MRI imaging data [12]. Inspired by the Ising spin-glass model representation of brain dynamics, self-organized patterns of connectivity form through the spontaneous fluctuations of random spins [13]. Spin-glass models have been used to characterize both complex microscale dynamics of the human brain [14–17] and macroscale interactions [18–23]. In fact, unconstrained maximum entropy models have been shown to accurately represent spatiotemporal coactivations in neuronal spike trains [23–26] and patterns of BOLD activity [26–29]. Recently, Zanoci and colleagues [30] demonstrated that the Ising model can capture collective neuronal behavior during wakefulness, light sleep, and deep sleep when both excitatory (E) and inhibitory (I) neurons are modeled.

Sex differences play an important role in AD risk, with females being more susceptible to *APOE*-related

pathogenic changes than males [31, 32]. Among other genetic and epigenetic factors, this risk may be attributed to hormonal differences, such as the protective effects of estrogen on neuronal function and synaptic plasticity, which decline during menopause in females, potentially increasing their susceptibility to *APOE*-related pathogenic changes like hyperexcitation [33, 34]. However, the field of clinical AD often treats sex as a covariate, limiting the potential for discovering interacting effects regarding disease progression [35]. Recent studies from the Alzheimer's Disease Neuroimaging Initiative (ADNI) suggest that approximately 75% of patients with AD are female and appear to progress to AD more often than males [36]. While the subjects of this study are unimpaired, our hypothesis is that our metric describing EIB can detect subtle shifts in hippocampal dynamics related to *APOE* or amyloid- β influences.

We apply our computational framework on a large cohort (OASIS-3: Open Access Series of Imaging Studies [37]) of individuals aged 42 to 95 years without cognitive impairment. The first aim is to test the hypothesis that female $\epsilon 4$ carriers would exhibit connectome signatures of hyperexcitation within hippocampal regions compared to non- $\epsilon 4$ carriers, which may confer a greater vulnerability to AD neuropathology. Moreover, we hypothesize that even females without elevated risk of developing AD (either through *APOE4* or $A\beta+$) also have diverging EIB compared to men, contributing to higher risk of *APOE* or amyloid-mediated effects of hyperexcitation. Lastly, we investigate sex differences in EIB concerning neuropsychological testing with a focus on hippocampal dynamics, which play distinct roles in detecting and monitoring cognitive and functional changes associated with dementia-associated diseases [38].

While studies assessing the effects of sex and *APOE4* or $A\beta+$ on specific MRI-based BOLD signal changes have produced varied results, early identification and intervention are critical to improving patient outcomes. We aim to expand on these sex differences, providing new insights and suggesting that a network with spatiotemporal structure may help in better understanding AD progression and identify subtle changes to neural dynamics before the onset of irreversible degeneration. This can lead to more informed therapeutic targets and early interventions to mitigate AD progression in vulnerable populations, potentially guiding the development of tailored, effective treatments and improving early diagnosis. Enhanced understanding of EIB dynamics could con-

tribute to personalized medicine approaches in AD, ultimately leading to better patient outcomes.

MATERIALS AND METHODS

Participants

The Open Access Series of Imaging Studies (OASIS-3) is a retrospective compilation of over 1000+ participants with imaging data collected over the course of 30 years across several ongoing projects at the Charles F. and Joanne Knight Alzheimer Disease Research Center at Washington University in St. Louis. These projects include the Memory and Aging Project, Adult Children Study, and Healthy Aging and Senile Dementia. In total, OASIS-3 comprises a diverse collection of clinical, neuropsychological, neuroimaging, and biomarker data for 1098 participants (age: 42–95 years). It is important to note that not all participants completed the full protocol, and only individuals aged 65 or older completed neuropsychological testing [39].

Thus, in this study we analyzed a cross-section of individuals with combined structural MRI, functional MRI, and PET imaging sessions ($N=437$), including *APOE* genotyping, extracted from (<https://central.xnat.org>). In this study, genotype was analyzed as a dichotomous variable defined as *APOE4* non-carriers ($\epsilon 3/\epsilon 3$ allele combination) and *APOE4* carriers ($\epsilon 3/\epsilon 4$ or $\epsilon 4/\epsilon 4$ allele combinations) since the $\epsilon 4$ allele is commonly associated with an increased AD risk [40–42]. Herein, NC will refer to *APOE4* non-carriers, and *APOE4* will refer to carriers of at least one $\epsilon 4$ carrier.

For the purposes of this study, we included only participants classified as cognitively normal (no impairment) according to the Clinical Dementia Rating (CDR) scale ($CDR=0$). Inclusion of only cognitively normal participants ($CDR=0$) ensures that the analysis focuses on individuals without any impairment, providing a clearer picture of the factors affecting healthy aging. We further excluded participants carrying one or more *APOE* $\epsilon 2$ alleles due to the neuroprotective effect associated with this allele against AD-related neurodegeneration [43, 44]. Consequently, this group could not be considered as part of either the control or carrier groups. Exclusion of participants carrying one or more *APOE* $\epsilon 2$ alleles eliminates potential bias introduced by the neuroprotective effect of this allele, resulting in a more accurate assessment of the impact of other factors on AD risk [45, 46].

We matched each MRI-PET session with the closest clinical session. For each participant, the first MRI-clinical-session pair with an absolute time difference of <1 year was selected as the baseline session. In cases where duplicate data were available for subjects, we used the earliest or initial MR imaging session. Using the earliest or initial MR imaging session for participants with duplicate data reduces the potential for confounding effects of disease progression or other time-dependent factors on the analysis. The aggregated participant information used in this study is presented in Table 1.

Cognitive assessment measures and neuropsychological testing

In this study, three screening measures were included to ensure that included subjects are without cognitively impairment: the Mini-Mental Status Examination (MMSE), Geriatric Depression Scale (GDS), and the CDR. The MMSE is a screening tool used to assess global mental status. It is comprised of an 11-question measure (scored from 0 to 30) assessing orientation, attention and concentration, registration, recall, and language. Scores below 24 have been shown to be effective in identifying individuals with possible cognitive impairment [47]. The GDS is a 30-item measure that assesses symptoms of depression in middle-aged and older populations. Scores above 10 indicate possible Major Depressive Disorder [48]. The standardized collection of OASIS-3 was developed at the Alzheimer's Disease Centers (ADC) program of the National Institute on Aging (NIA) as a central component of the Uniform Data Set (UDS) [49, 50]. Here, the clinical labeling of dementia severity was determined based on the CDR. The CDR is a semi-structured interview intended to provide a global dementia severity rating, which is commonly employed for staging and tracking decline in AD [51, 52]. The score here represents multiple levels of functional impairment (0=no impairment; 0.5=questionable or very mild impairment; 1=mild impairment; 2=moderate impairment) and summarizes the estimate of dementia severity [53, 54]. As mentioned in the previous section, this study comprises only of individuals with a CDR equal to zero (signifying no impairment).

Further, the protocol used in the OASIS-3 for neuropsychological testing consists of a battery based on the Uniform Data Set (UDSNB), which was developed in ADC to establish a standardized data collection system [55]. Participants aged 65 and

Table 1
Demographics and screening measures of participants from OASIS-3 [39] used in this study.
All subjects are cognitively normal with CDR = 0

	Females (N = 269)	Males (N = 168)	<i>p</i>
Age (y)	67.6 (9.3)	68.3 (8.9)	1.0
APOE Alleles			
$\epsilon 3/\epsilon 3$	170 (27 A β +)	104 (19 A β +)	
$\epsilon 3/\epsilon 4$	82 (29 A β +)	58 (27 A β +)	
$\epsilon 4/\epsilon 4$	17 (11 A β +)	6 (3 A β +)	
Total APOE $\epsilon 4$	99	64	1.0
Total A β +	67	49	1.0
Education (y)	15.5 (2.5)	16.7 (2.6)	<0.001
MMSE (total)	29.2 (1.1)	29.0 (1.3)	1.0
GDS (total)	1.3 (1.7)	1.2 (1.6)	1.0
rs-SC Quality (S_m)	0.95 (0.01)	0.95 (0.01)	1.0
rs-SC Quality (max f_c)	0.88 (0.02)	0.88 (0.02)	1.0
EIB – Whole Brain	1.26 (0.08)	1.27 (0.08)	1.0
EIB – Right Hippocampus	1.35 (0.35)	1.37 (0.31)	1.0
EIB – Left Hippocampus	1.35 (0.32)	1.32 (0.31)	1.0

Mean values (SD), Holm-corrected *p*-values; EIB, excitation-inhibition balance; rs-SC, hybrid resting-state structural connectome; MMSE, Mini-Mental State Exam; GDS, Geriatric depression scale.

older completed a battery of neuropsychological tests at the ADRC to evaluate several tests measuring attention, working memory, executive function, processing speed, language, and episodic memory. Logical Memory - Story A, a subtest of the Wechsler Memory Scale-Revised, measures episodic memory. Participants recall as many details as they can from a short story containing 25 bits of information after it is read aloud by the examiner (LM-I) and again after a 30-minute delay (LM-II, with scores ranging from 0 (no recall) to 25 (complete recall)). Semantic memory and language were measured using the Category Fluency test, requiring participants to name as many words belonging to a category, animal and vegetable, in 60 seconds, and the Boston Naming Test, in which participants name drawings of common objects. Psychomotor speed was measured using the WAIS-R Digit Symbol test and the Trail Making Test Part A. The WAIS-R Digit Symbol test is scored on the number of digit symbol pairs completed in 90 seconds. Executive function was measured using the Trail Making Test Part B. In the Trail Making Test participants were asked to make a trail by connecting a series of numbers (1–26) for part A and connecting a series of alternating numbers and letters (1-A-2-B) for part B. The outcome measure used in this manuscript is the total time to complete in seconds with a max of 150 s for Trails A and 300 s for Trails B. A complete description of cognitive assessment measure and neuropsychological testing completed for the OASIS-3 dataset can be found

in the data dictionary (<https://www.oasis-brains.org/>).

MRI and PET imaging

MRI and PET imaging used in this study from the OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive dataset for Normal Aging and Alzheimer's disease [37] was collected in a 16-channel head coil of a Siemens TIM Trio 3T scanner. In this study, only cognitively normal individuals with structural (Diffusion-weighted imaging and T1-weighted imaging), resting-state functional (fMRI) and PET imaging were included. Processing of the MRI imaging is described in the Supplementary Material detailing the processing of structural and functional networks, as well as the procedure for constructing a hybrid resting-state structural connectome. In short, our team recently combined MRI-derived multimodal connectome data (resting-state functional and structural) with statistical physics to obtain a macroscopic account of inhibitory and excitatory long-range connections [12, 56]. Here, we employed the Ising model, a well-known spin-glass model from statistical physics in which the states, also referred to as “spin configurations”, of interacting units – in our case brain regions connected by white matter edges – are constrained to be either 1 (“active”) or –1 (“inactive”). As described previously [12, 56], we construct a function-by-structure embedding (FSE) using a constrained pseudolikelihood estimation technique

wherein pairwise interaction coefficients are inferred from the observed data (BOLD time series) and underlying structural connectome, resulting in a spatiotemporal network describing both structure and function (called the hybrid resting-state structural connectome, or rs-SC).

Note that although our framework for constructing the rs-SC does not explicitly model brain activity at a neuronal level, several seminal studies have used the Ising model to investigate neuronal firing patterns with success, showing that ensemble level activities can be well explained by pairwise Ising interactions [24, 57]. To be clear, from a connectomics perspective, if several brain regions are identified to have an increase in positive edges in the rs-SC, collectively, that would suggest a wider-spread pattern of coupling (i.e., more likely to exhibit a pattern of global coupling) that may subserve hyperexcitation. It is in this context that we conceptualize the Excitation-Inhibition (E-I) ratio, a global (whole-brain) or local (ROI-level) estimation of EIB, computed as the sum of positive edges divided by the sum of negative edges. For example, if a brain region in the network has 45 positive interactions (edges) and 34 negative interactions with other brain regions, then the E/I ratio = 45/34, or 1.32 (a value of 1 indicates perfect EIB).

PET imaging included both [¹¹C]-Pittsburgh compound B, as well as Florbetapir ([¹⁸F]-AV45). The PET image processing steps can be found in the data dictionary (<https://www.oasis-brains.org/>). For this study, we utilized the partial volume corrected mean cortical Standard Uptake Value Ratio (SUVR) with regional spread function (SUVR rsf) provided in the dataset database (<https://central.xnat.org>). To assess global amyloid burden based on the PET imaging, the mean cortical SVUR was defined as the arithmetic mean of SUVRs from the precuneus, prefrontal cortex, gyrus rectus, and lateral temporal regions (include citations). A positive amyloid- β PET scan ($A\beta+$) was defined as having a mean cortical SUVR rsf > 1.42 for [¹¹C]-Pittsburgh compound B PET or SUVR rsf > 1.19 for Florbetapir PET [39, 58]. For simplicity with two different PET tracers utilized in this dataset, in the ensuing analyses we treat $A\beta$ as a dichotomous variable wherein an individual may be either $A\beta-$ or $A\beta+$.

Statistical analysis

Demographic, screening and clinical measures for males and females were compared using the

Wilcoxon rank-sum tests for continuous variables and Fisher's exact test for categorical variables. These non-parametric tests were chosen due to their robustness to non-normality and applicability to small or unbalanced sample sizes. The statistical tests were initially used to identify differences in demographic, screening, or clinical measures between males and females. However, the decision to include these variables as covariates in the regression models was also based on their potential impact on the outcome variables as informed by existing literature. This consideration led to the addition to the AD risk factors being evaluated ($\epsilon 4$ carriers (*APOE*)/non-carriers (NC), sex, age, and amyloid- β positivity ($A\beta+$ / $A\beta-$).

Whole-brain and hippocampal EIB were evaluated using linear regression models, which allowed us to estimate the relationships between the predictors and the outcome variables, as well as assess potential interaction effects. Three separate regression models were tested (with sex = 1 for females and sex = 0 for males): The first regression model examined EIB as a function of age and sex interactions for cognitively normal males and females without any known predispositions to AD neuropathology (i.e., individuals with CDR=0, $A\beta-$, and *APOE* $\epsilon 3/\epsilon 3$ allele combinations). This model aimed to identify and evaluate the progression of EIB between sexes under normal-aging conditions (N = 228, 143 Female) without any known genetic risk factors for AD. The second regression model assessed EIB as a function of age and *APOE* interactions for individuals that are $A\beta-$ to evaluate the influence of the *APOE4* allele on EIB in healthy aging (N = 321, 202 Female). *APOE* is a dichotomous variable indicating individuals with at least one *APOE4* allele or none ($\epsilon 3/\epsilon 3$). The third regression model examined EIB as a function of the interactions between age, *APOE*, and amyloid (allowing for up to 4-way interactions between predictors), as well as two-way interactions of *APOE* – amyloid when controlling for other confounds (N = 437, 269 Female). Amyloid positivity is a dichotomous variable ($A\beta+$ / $A\beta-$) based on thresholding of SUVR data from PET imaging, as described in the methods section. This model was analyzed separately for each sex to investigate the effect of $\epsilon 4$ and amyloid on EIB specific to males and females.

Lastly, we tested for relationships between cognitive measures, neuropsychological tests, and EIB for each sex using partial correlation analysis to control for age, *APOE*, and amyloid as confounds.

Partial correlation analysis was chosen as it allows for the evaluation of the association between two variables while controlling for the effects of other variables. We further performed correlation analysis to test for associations between EIB and screening measures (MMSE, GDS, Education). p -values were adjusted for multiple comparisons using the Holm correction to control the family-wise error rate and reduce the likelihood of false positives. A p -value <0.05 was considered statistically significant, and $p < 0.1$ was considered marginally significant. Analyses were conducted in MATLAB R2021b.

RESULTS

Computationally inferring excitation-inhibition balance from MRI imaging data

We compute excitation-inhibition balance (EIB) for the whole-brain as well as for left and right hippocampal regions as determined by the Harvard-Oxford Atlas used in the processing of the MRI imaging. Here we follow the three-stage process for obtaining an optimized hybrid resting-state structural connectome (rs-SC) via a function-by-structure (FSE) embedding. To evaluate the quality of the generated rs-SC, we compute the similarity metric and evaluate the quality of reconstructing observed FC. As described in the Supplementary Material, the similarity metric S_m evaluates the constraint and is computed as the correlation between the magnitude of rs-SC and the structural connectome. The $\max f_c$ metric measures the quality of reconstructing observed FC using Monte Carlo simulations of the Ising model with our rs-SC being used to define the interaction network. The value for structural similarity (S_m) in this dataset is 0.9, the max is 0.98, with a mean of 0.95 and variance of 0.0001. The minimum correlation between observed and simulated FC ($\max f_c$) in this dataset is 0.82, the maximum is 0.93, the mean is 0.88 with variance of 0.0004. This suggests that the FSE framework works well in constructing the hybrid connectome with low inter-subject variability. From the rs-SC, we compute E-I by summing the positive edges in the network (excitatory interactions) divided by the negative edges in the network (inhibitory interactions). This is computed for the whole brain (105 ROIs) as well as isolating the bilateral hemispheres of the hippocampus (left and right) for further analyses.

Excitation-inhibition balance of cognitively normal individuals without APOE4 or significant amyloid

With EIB computed for each subject at the whole brain and hippocampal levels, we first evaluate sex differences in EIB for cognitively normal individuals without known risks of developing AD (e.g., $APOE \epsilon 3/\epsilon 3$ and $A\beta^-$). A subset of subjects from Table 1, we note only a statistically significant difference in male ($N = 85$) and female ($N = 143$) education (in years) with Holm-corrected $p < 0.001$, noting that on average the females in this group have less education (15.5 years) as compared to males (16.7). As a result, we account for education in our regression models due to significant group difference between males and females. In Fig. 1, we present the progression of global EIB and hippocampal EIB (left and right). Here, linear regression analysis evaluating whole-brain EIB with interaction effects of age $\times$ sex result in $p = 0.021$ ($\beta = -0.002$, $SE = 0.001$), suggesting that males may have a greater increase in global inhibitory tone than females (or decrease in excitatory interactions). No difference is found for this subset of the OASIS-3 cohort in terms of hippocampal EIB. The result presented in the figure suggests that females maintain EIB from middle age to old age better than men, potentially a result of some compensatory mechanisms to a decline in excitatory tone. Regression results including estimates, p -values and standard error for all main and interaction effects are shared in Supplementary Table 1. Sensitivity analysis was performed using Cook's Distance for outlier detection in our model. Exclusion of this outlier resulted in only marginal changes in our regression analysis without significant changes to results or overall conclusion, suggesting that the influence of this single data point on the estimated regression line is minimal. Therefore, the inclusion or exclusion of this outlier did not significantly impact the overall results, lending further credibility to our conclusion that men may have a greater increase in global inhibitory tone than women (or decrease in excitatory interactions) in the absence of AD risk factors.

Influence of APOE $\epsilon 4$ on excitation-inhibition balance

Additionally in this study we aimed to evaluate on a larger scale, findings from our previous investigations of sex differences in EIB with respect to




Fig. 1. Progression of EIB in cognitively normal males and females without AD risk factors (*APOE* $\epsilon 3/\epsilon 3$, and $A\beta^-$). Progression of global EIB suggests that males may have a greater increase in inhibitory tone than females with age (or decrease in excitatory interactions). Linear mixed effects regression analysis evaluating the interaction effects of age $\times$ sex result in $p = 0.021$ ($\beta = -0.002$, $SE = 0.001$). No group differences were identified in the right or left hippocampus. Results suggest that EIB is more stable in females than males with increasing age (in absence of AD risk factors), perhaps due to some underlying compensatory mechanisms.

the *APOE4* allele [12, 59], namely that cognitively unimpaired females with at least one *APOE4* allele exhibit shifts in excitatory interactions which may confer greater vulnerability to AD neuropathology. Specifically, here we evaluate the progression of EIB with respect to age for whole-brain and hippocampal regions for males and females separately to elucidate the impact of the *APOE* genotype. Presented in Fig. 2 is a comparison of hippocampal EIB progression for cognitively normal males ($N = 119$) and females ($N = 202$) that are $A\beta^-$. While our data is not age or sex-matched as in our previous work, Fig. 2 includes whole-brain comparisons for male and female *APOE* carriers and non-carriers (NC) based on linear regression analysis. While there is a group difference in whole-brain EIB between female *APOE* carriers and non-carriers, the difference can be partially explained by age differences in this cross-section, resulting in a p -value of $p = 0.061$ ($\beta = 0.02$, $SE = 0.01$) for the main effect of *APOE* status. Visually, only the right hippocampus diverges for female *APOE4* carriers as

compared to non-carriers. Linear regression analysis evaluating the interaction effects of age $\times$ *APOE* for females results in $p = 0.013$ ($\beta = 0.014$, $SE = 0.005$). No significant group difference was identified in whole-brain dynamics for either sex, the left hippocampus for women, or for either side of the hippocampus for men. This result suggests that cognitively normal females that are *APOE4* carriers and amyloid negative exhibit an increasing effect with age in the EIB of the right hippocampus as compared to non-carriers in the absence of significant amyloid. Regression results including estimates, p -values, and standard error for all main and interaction effects are shared in Supplementary Table 2.

*Excitation-inhibition balance in the presence of *APOE4* and $A\beta$*

With the inclusion of individuals with significant $A\beta$ deposits for both *APOE4* carriers and non-carriers as described in Table 1, we aim to determine results




Fig. 2. Progression of EIB in cognitively normal males and females, comparing *APOE4* and non-carrier (NC) groups that are A β -. Top panel: whole-brain comparisons for male and female *APOE4* carriers and non-carriers (NC) based on linear regression analysis. While there is a group difference in whole-brain EIB between female *APOE4* carriers and non-carriers, the difference can be partially explained by age differences in this cross-section, resulting in a *p*-value of 0.06 for the main effect of *APOE4* status. Middle and Bottom Panels: Here, only the right hippocampus for females demonstrates divergence for *APOE4* carriers as compared to non-carriers. Linear regression modeling to evaluate the interaction of age $\times$ *APOE4* results in *p* = 0.013 (β = 0.014, SE = 0.005). Results suggest that females *APOE4* carriers exhibit an increasing effect in EIB in the right hippocampus as compared to non-carriers in the absence of significant amyloid deposits. No significant group differences were identified in the left hippocampus for females or for either side of the hippocampus for men.

for three cases in the linear modeling of sex difference in whole brain and hippocampal EIB. First, we evaluate age $\times$ APOE interaction, second, we evaluate age $\times$ Amyloid interactions, and third we evaluate APOE $\times$ Amyloid interactions (noting here that both APOE and amyloid are dichotomous variables). In Fig. 3, we present a comparison of hippocampal EIB progression for cognitively normal males and females that are A β +. The right hippocampus appears to be significant for both males and females with diverging progression between APOE carriers and non-carriers; however, linear regression analysis evaluating interaction effects of age $\times$ APOE results in $p=0.012$ ($\beta=0.014$, S.E.=0.012) for the right hippocampus of females only. Regression results are insignificant for males ($p>0.1$). Further, linear regression modeling identified a marginally significant interaction effect of age and amyloid status with $p=0.07$ ($\beta=-0.02$, S.E.=0.012) for the left hippocampus in females only. No other interaction effects have any significance. Regression results including estimates, p -values, and standard error for all main and interaction effects are shared in Supplementary Table 3. This suggests that the association of EIB with age for both men and women may be affected by amyloid plaques, with more significant differences in female APOE4 carriers.

Relationship between excitation-inhibition balance and neuropsychological tests

To evaluate the relationship between EIB for whole-brain dynamics as well as for the hippocampal regions, we perform partial correlation analysis between the neuropsychological test completed in this cohort and EIB of the whole-brain, as well as the left and right hippocampus (for each sex separately). Here we are controlling for primary co-factors of age, APOE4, amyloid status (with the latter two being dichotomous variables), and education due to significant group differences between males and females (shown in Table 1). The screening measures of subjects are presented in Table 2, noting that they are a subset of the overall 437 used in this study. Further, as presented in Table 2, we note significant differences between males and females for learning memory task I (LM-I), learning memory task II (LM-II), category fluency for vegetables, and the Boston naming test ($p<0.05$).

Partial correlation analysis of EIB for the whole-brain, as well as left and right hippocampus with neuropsychological measures are presented in Fig. 4.

Statistically significant correlations are indicated with a star (Holm-corrected $p<0.05$), with all results presented in Table 3. The plot in Fig. 4 highlights differences in both whole-brain and hippocampal relationships with neuropsychological tests in females when controlling for well-known covariates in this dataset related to susceptibility of AD neuropathology. Here, the partial correlation of EIB of the right hippocampus with categorical fluency (ANIMALS) is significant ($p<0.05$) and marginally significant with logical memory tests ($p<0.1$). Further, the partial correlation of EIB of the whole-brain with trail making test B is significant ($p<0.05$) and marginally significant with Trail Making test A ($p<0.1$). We note that the performance in Trail Making tests is measured in seconds to completion, hence shorter times imply better performance. Both sets of results are specific to the female group. Partial correlations of EIB with neuropsychological tests are insignificant for the male group when controlling for co-factors of age, APOE, and amyloid status. Further, there is a more right hemispherical dominance in terms of hippocampal EIB for females compared to left hemispherical dominance for males in most tasks, however males do not have any statistically significant correlations between EIB of the hippocampus or whole-brain with these neuropsychological tests when controlling for co-factors of age, APOE, and amyloid status, and education. This, in contrast to females that do have more significant relationships with the right hippocampus. We note here the pattern of Trail Making tests having more influence from whole-brain dynamics than either hippocampal region for both males and females (albeit more significantly for the latter).

DISCUSSION

The present study was conducted to determine how EIB in cognitively normal individuals may be associated or influenced by AD risk factors such as age, sex, APOE genotype, and A β . Using a framework based on statistical physics, we computationally inferred EIB to macroscopically evaluate whole brain and hippocampal signatures of hyperexcitation. The novelty of this model lies in integrating microscale principles at a connectome level to bridge the gap between cell-to-network level degeneration. We previously demonstrated age- and sex-dependent hyper-excitation within regions of the default mode network in a cohort of A β - cognitively normal female




Fig. 3. Hippocampal EIB progression for cognitively normal males and females that are Aβ⁻/Aβ⁺ (with and without *APOE4*). Panels from top to bottom (A–D): first is a comparison of hippocampal EIB progression in the absence of known AD risk factors (*APOE4* and Aβ⁺), then hippocampal EIB progression for amyloid negative (Aβ⁻) individuals with at least one *APOE4* allele, followed by hippocampal EIB progression of amyloid positive (Aβ⁺) that are non-carriers (NC) of *APOE4*, and last is hippocampal EIB progression for individuals that are *APOE4* carriers and also Aβ⁺. These plots suggest that in the presence of significant amyloid (Aβ⁺), divergence between *APOE* carriers and non-carriers is significant in the right hippocampus for males and females, however regression modeling to evaluate the interaction effects of age × *APOE4* results in $p=0.012$ ($\beta=0.014$, S.E. = 0.012) for females only. Further, linear regression modeling identified a marginally significant interaction effect of age and amyloid status with $p=0.071$ ($\beta=-0.02$, S.E. = 0.012) in the left hippocampus for females as well. Regression results are insignificant in the hippocampus (right and left) for males ($p>0.1$). Results suggest that features of hyperexcitation (increasing EIB) in hippocampal regions may be driven by *APOE4* rather than amyloid for cognitively normal individuals, with more significant impact on females.

Table 2
Demographics, and screening measures of participants from OASIS-3 [39] used in secondary analyses involving neuropsychological testing (a subset of those presented in Table 1). All individuals are cognitively normal (CDR = 0) with completed neuropsychological testing

	Females (N = 138)	Males (N = 93)	<i>p</i>
Age (y)	72.3 (6.2)	72.1 (6.1)	1.0
APOE Alleles			1.0
$\epsilon 3/\epsilon 3$	89 (19 A β +)	57 (16 A β +)	
$\epsilon 3/\epsilon 4$	42 (19 A β +)	33 (18 A β +)	
$\epsilon 4/\epsilon 4$	7 (5 A β +)	3 (2 A β +)	
Total APOE $\epsilon 4$	49	36	1.0
Total A β +	43	36	1.0
Education (y)	15.1 (2.5)	16.7 (2.6)	0.011
MMSE (total)	29 (1.2)	28.9 (1.3)	1.0
GDS (total)	1.3 (1.8)	1.2 (1.6)	1.0
LM-I	14.6 (3.9)	13.1 (3.9)	<0.001
LM-II	13.9 (4.4)	12.5 (4.1)	0.052
ANIMALS	20.8 (5.7)	21.3 (5.1)	1.0
VEGETABLES	16.1 (3.9)	13.2 (3.3)	<0.001
TRAIL-A	33.8 (12.3)	34.3 (14.5)	1.0
TRAIL-B	90.1 (49.3)	80.9 (27.9)	1.0
WAIS-R	57.1 (13.2)	53.9 (10.2)	0.322
BOSTON	27.4 (2.5)	28.3 (1.9)	0.031

Mean values (SD), Holm-corrected *p*-values; MMSE, Mini-Mental State Exam; GDS, Geriatric depression scale; Scored neuropsychological tests (higher scores imply better performance): LM-I, Logical Memory task; LM-II, delayed Logical Memory; WAIS-R, Wechsler Adult Intelligence Scale; BOSTON, Boston naming test; ANIMALS and VEGETABLES, category and letter fluency test; timed neuropsychological tests (lower scores imply better performance): TRAIL-A and TRAIL-B (Trail Making Tests).




Fig. 4. Partial correlation analysis of EIB (whole-brain, left and right hippocampus) and neuropsychological testing for females, controlling for co-variables of age, *APOE4*, and amyloid status. Presented here are partial correlation analysis of EIB for the whole-brain, as well as left and right hippocampus with neuropsychological measures. Statistically significant correlations are indicated with two stars (Holm-corrected $p < 0.05$) and partially significant correlations are indicated with a single star (Holm-corrected $p < 0.1$). There are no statistically significant (or marginally significant) results for males, and therefore are not included in this figure (all results for both sexes included in Table 3). The plot here highlights differences in both whole-brain and hippocampal relationships with neuropsychological tests when controlling for well-known covariates in this cognitively normal cross-section in terms of susceptibility to AD neuropathology. Here, performance in category fluency tests (ANIMALS) demonstrates a significant positive correlation of the right hippocampus, while performance in trail making test B is significantly correlated with the EIB of the whole-brain. We further note that logical memory tests (I, II) have marginally significant positive partial correlations with right hippocampus EIB as well, while trail making test A is also marginally significant with whole-brain EIB. We note that for trail-making tests, performance is determined by the shortest time to completion, so negative correlations indicate a positive association with performance. Further, visually we see a hemispherical dominance in terms of right hippocampal EIB with neuropsychological test performance. We note here the pattern of Trail making tests having more influence from whole-brain dynamics than either hippocampal region for both males and females (albeit more significantly for the latter). In sum, results suggest that increasing EIB of the hippocampus seen in females, particularly those at increased risk of developing AD, correlated with improved performance in neuropsychological tests for females.

Table 3

Partial correlation analyses of EIB and neuropsychological testing, controlling for the effects of age, sex, *APOE4*, and amyloid status

	Whole-Brain		Hippocampus (right)		Hippocampus (left)	
	Females	Males	Females	Males	Females	Males
LM – I	0.011 (0.9)	–0.084 (1.0)	0.22 (0.078*)	–0.043 (1.0)	–0.004 (0.965)	–0.261 (0.1)
LM – II	0.041 (1.0)	–0.047 (0.66)	0.21 (0.097*)	–0.063 (1.0)	–0.013 (1.0)	–0.21 (0.213)
ANIMALS	0.048 (1.0)	–0.082 (1.0)	0.23 (0.048**)	–0.029 (1.0)	0.027 (1.0)	–0.161 (0.517)
VEGETABLES	–0.026 (1.0)	0.133 (1.0)	0.072 (0.413)	0.112 (1.0)	0.019 (1.0)	0.243 (0.152)
TRAIL - A	–0.21 (0.098*)	–0.184 (0.652)	–0.1 (0.75)	–0.112 (1.0)	–0.051 (1.0)	0.062 (1.0)
TRAIL - B	–0.252 (0.034**)	–0.113 (1.0)	–0.1 (0.951)	–0.112 (1.0)	–0.144 (0.855)	–0.016 (0.886)
WAIS-R	0.133 (0.731)	0.061 (1.0)	0.142 (0.49)	0.025 (0.821)	–0.009 (1.0)	–0.1 (1.0)
BOSTON	0.067 (1.0)	0.182 (0.721)	0.082 (0.662)	0.133 (1.0)	0.041 (1.0)	0.252 (0.148)

Linear partial correlation coefficient β (Holm-corrected p -values), scored neuropsychological tests (higher scores imply better performance): LM-I, Logical Memory task; LM-II, delayed Logical Memory test; WAIS-R, Wechsler Adult Intelligence Scale; BOSTON, Boston naming test; ANIMALS and VEGETABLES, category and letter fluency test; timed neuropsychological tests (lower scores imply better performance): TRAIL-A and TRAIL-B (Trail Making tests). * Adjusted $p < 0.1$; ** Adjusted $p < 0.05$.

carriers of *APOE4* allele [12, 59] where traditional measures of functional connectivity were unable to detect the subtle differences in brain dynamics between female carriers and non-carriers in middle age [60, 61]. Several studies have investigated EIB as an effect of the normal aging and neurodevelopmental process [3, 62–64]; however few incorporate known sex-differences in brain activity and development [65].

The results presented herein demonstrated that in the absence of AD risk factors (*APOE* $\epsilon 4/\text{A}\beta+$), whole-brain EIB progresses differently between males and females with age, with males decreasing more significantly as they get older. Further, performing regression modeling with the inclusion of individuals having at least one *APOE* $\epsilon 4$ allele ($\text{A}\beta-$) produced a significant age-by-*APOE* interaction in the right hippocampus for females only. The effect remained unchanged with inclusion of $\text{A}\beta+$ individuals. Last, we performed partial correlation analyses between EIB and neuropsychological testing, revealing positive associations between hippocampal and whole-brain EIB with test performance (for females only). Significant relationships between EIB in the right hippocampus with categorical fluency and whole-brain EIB with a trail-making test were identified. Each of these results will be discussed below.

The investigation in the context of normal aging is based on $N = 228$ (143 Female) individuals that have the *APOE* $\epsilon 3/\epsilon 3$ combination and classified as $\text{A}\beta-$. We note as mentioned in the methods section, the exclusion of individuals with the *APOE* $\epsilon 2$ allele. Deciding whether to include or exclude subjects with additional allele combinations including *APOE* $\epsilon 2$ merits further discussion. In this study, we aimed to expand on our previous work in a larger cohort

evaluating EIB as a potential MRI-based biomarker demonstrating pathophysiological differences in males and females that may confer latter greater vulnerability to AD neuropathology. By including individuals with additional allele combinations, we would then have to include an additional variable in our analysis, namely allele pair combinations. While it may provide additional insight into an EIB spectrum among different allele combinations, it would also decrease the statistical power of our results as some allele combinations would have significantly fewer subjects than others for each sex (even more so when breaking down by amyloid positivity as well). Our future work will aim to drill down further, beyond simple $\epsilon 3-\epsilon 4$ comparisons to better understand the relationship between the allele combinations and EIB. Here, our study demonstrates that alterations in the EIB are complex mechanisms that are associated with aging, sex, and the *APOE4* genotype before cognitive impairment occurs. Interestingly, we observed a reduction in EIB with age in males, presented in Fig. 1, which may be protective against hyperexcitability. It has been reported that alterations of tonic inhibition lead to hyperexcitability, which could contribute to the development of neurodegenerative diseases [66]. Thus, the reduction of excitation with aging in males might serve as a protective mechanism against neurodegeneration. Further research is needed to determine the underlying mechanisms of this phenomenon and its implications for disease progression. We acknowledge that it is difficult to interpret whether females have increased excitatory tone or males have increased inhibitory tone with respect to healthy aging and what other factors may be involved (genetic, hormonal, physiological, etc.).

These sex differences are highlighted further with the inclusion of individuals with *APOE* $\epsilon 4$ and pro-

vide additional support to our previous findings in that females with at least one *APOE4* allele are at higher risk of AD neuropathology due to a hyperexcitation of critical brain regions. Specifically, we found that EIB diverges significantly in the right hippocampus for female carriers, with no change in either side of the hippocampus for males. Shown in Fig. 2, these findings are biologically significant in the following two important ways:

- 1) They are consistent with the recently proposed theory of a hyper-excitable state in the earliest AD pathology, due to the susceptibility of inhibitory GABAergic interneurons to ApoE4 fragment-mediated neurotoxicity (in the dentate gyrus of hippocampus).
- 2) They may help explain sex differences in AD (females are at a substantially greater risk of developing AD) by linking the earliest pre-clinical changes of AD pathology, i.e., hyper-excitability in the hippocampus, to reported sex-differences in functional connectivity developed in early adulthood and sustained across the life span. Indeed, fMRI studies have shown that females exhibit higher resting-state functional connectivity in the temporal lobe, and thus likely a differentially higher excitation relative to inhibition). Given the complexity multifactorial nature of AD, network-level neuroimaging metrics may be more sensitive to subtle structural and functional disruptions than traditional analyses [67, 68].

In fact, our results suggest that *APOE*, but not amyloid, may be the driver for increased EIB deviations as demonstrated by the interaction effect of *APOE* and age, having no change in statistical significance with the inclusion of A β + individuals. However, in this cohort (OASIS-3), the cognitively normal group is heavily skewed in terms of A β - individuals, which may result in low statistical power for differentiating between *APOE* and amyloid-mediated effects in this cross-section. In our analysis, we recognize several limitations that may impact the interpretation of our findings. An age-matched cohort was not included in our comparisons, an aspect which may have influenced our results and interpretation. Inclusion of an age-matched cohort in the future may allow for a more robust comparison and analysis of an *APOE4* effect. Further, our study lacks information regarding tau load, preventing the study of EIB with relation to the triad of AD risk (*APOE4*, amyloid, and tau)

in terms of healthy aging and AD risk. Some studies have found that the interaction effect between *APOE4* and amyloid- β , rather than the sum of their independent effects, was related to increased tau load in AD-vulnerable regions [69, 70]. This may help to explain the lack of interaction between *APOE4* and A β . The interaction between one *APOE4* allele and A β is hypothesized to be related to increased tau load, while the interaction between A β and two *APOE4* alleles was related to a more widespread pattern of tau aggregation [69, 71]. With A β -mediated hyper-excitation emerging as a promising candidate mechanism of AD pathogenesis: inhibitory GABAergic dysfunction is predictive of increased neuronal activity, while the increased damage of dendrites may be associated with a silencing effect of neuronal circuits (the yin and the yang of AD degeneration). However, recent evidence however, points to hyper-excitability of neuronal circuits as a precursor to the formation of amyloid plaques [70, 72, 73], and a major driver of the cascading effect of tau pathology, propagating from the entorhinal cortex to the hippocampus and beyond to other cortical regions [74]. In fact, one study has even demonstrated differential effects of sex by *APOE* interaction on tau accumulation, in that only one *APOE* ϵ 4 allele is sufficient to increase tau accumulation in females, while two *APOE* ϵ 4 alleles are needed to cause a similar effect in males [75]. In future studies, we aim to identify EIB changes which may be related to *APOE*, A β , and tau in healthy aging as well as in individuals that are cognitively impaired and/or have AD to identify a more complete picture of EIB progression in relation to neurodegeneration and these risk factors. The complex, multifactorial nature of AD makes it essential that we continue to develop techniques to meaningfully integrate multiple neuroimaging modalities to increase the sensitivity to detect very early network aberrations associated with risk for this disease.

Last, we found an association between EIB and neuropsychological testing, specifically in females when controlling for age, education, *APOE*, and amyloid positivity. We note that while it is true that amyloid presence is a defining feature of AD pathology, it is also a risk factor that may precede the clinical manifestations of the disease. Controlling for amyloid status allows us to account for the influence of preclinical AD pathology on the observed associations between EIB and neuropsychological variables. Further, including both *APOE* and amyloid in the study of hyperexcitation differences in cognitively normal individuals allows us to account for potential

genetic and pathological influences on neural activity, as both factors have been implicated in the development and progression of AD.

As shown in Fig. 4, partial correlation analyses revealed positive associations between EIB and neuropsychological testing for females, having significant relationships between EIB in the right hippocampus with categorical fluency and whole-brain EIB with a trail-making test. Performance in category fluency tests (ANIMALS) is significantly correlated with EIB of the right hippocampus for women, while performance in trail making test B is significantly correlated with the EIB of the whole-brain. We further note that logical memory tests (I, II) have marginally significant partial correlations with EIB of the right hippocampus as well, while trail making test A is also marginally significant with whole-brain EIB. We should clarify that the partial correlations we've presented highlight the unique contribution of EIB to neuropsychological performance, independent of the influence of covariates such as age, education, *APOE*, and amyloid status. For example, a lower partial correlation between left hippocampal EIB and verbal memory tasks does not necessarily signify a negligible overall association. The traditionally acknowledged association between left hippocampus and verbal memory could indeed be a downstream consequence of factors such as *APOE* and amyloid.

Further, there is also a more hemispherical dominance in terms of hippocampal EIB however males have no significant correlations in the EIB as compared to females that have more significant relationships with the right hippocampus. The observed association between right hippocampal EIB and verbal memory tasks, as opposed to left hippocampal (left) EIB, might appear surprising given the traditional view of left hippocampus being more involved in verbal memory processing. However, recent research has suggested that the lateralization of memory functions is more complex than initially thought, with some studies showing the involvement of both sides of the hippocampus in verbal memory tasks [76, 77]. To that end, these results shed light on a pattern of hemispheric dominance in the hippocampus, with women demonstrating a stronger correlation with the right hippocampal EIB. This finding might suggest sex-specific patterns of hippocampal involvement within the context of AD risk, a potentially important consideration when assessing the cognitive status and potential AD risk of female patients. Further research is needed to confirm this hypothesis and better understand the underlying

mechanisms. We note here the pattern of Trail Making tests having more influence from whole-brain dynamics than either hippocampal region for both males and females (albeit more significantly for the latter). The pattern of Trail Making tests having more influence from whole-brain dynamics than hippocampal regions for both males and females suggests that these tests might be more sensitive to global cognitive changes associated with AD risk, rather than being specific to hippocampal function [78]. This further highlights the importance of considering sex-specific differences when evaluating the relationship between EIB and cognitive performance in the context of AD risk. Further, while our analysis does control for factors like *APOE* and amyloid status, it is crucial to note that our intention is not to dismiss the role of AD risk factors. Instead, we aim to delve deeper into the independent role of EIB in cognitive performance, beyond these known risk factors.

These results suggest that increasing EIB is correlated with improved performance in neuropsychological tests for females and related two ongoing hypothesis; the first being that increased excitation (a positive shift in EIB) is associated with better performance in neuropsychiatric testing (as others have demonstrated with transcranial magnetic stimulation and transcranial direct current stimulation [79, 80]), and second being that potential hyperexcitation due to *APOE* $\epsilon 4$ both precedes and may even influence increased spread of amyloid plaques before cognitive impairment is identified [81]. It is also possible that the *APOE* $\epsilon 4$ genotype may be protective against a subtle deficit associated with A β pathology, and consistent with the antagonistic pleiotropy hypothesis; whereby a gene controls both beneficial and detrimental traits, and provides novel evidence that these effects persist into older age, even among individuals who cognitively unimpaired (but may have additional AD risk factors) [82–84]. Despite strong evidence of the clinical utility of neuropsychological tests; however, it is unclear what neurobiological information the test scores provide. While the progression of the pathophysiological process of dementia strongly affects neuropsychological function [85, 86], a large amount of variance is left unexplained even with multimodal biomarker information [87–89]. Moreover, it is hard to predict whether the presence of pathophysiological markers directly leads to neural dysfunction within the behaviorally relevant regions [90].

Further, the cross-sectional design of our study precludes us from making causal inferences about the relationship between EIB and AD neuropathol-

ogy. Longitudinal analysis would be necessary to investigate EIB as a predictor of individuals who subsequently develop AD neuropathology. In addition, neuropsychological test data was only available for individuals aged 65 or older, which may limit the generalizability of our findings to younger populations. Last, we recognize that hormonal differences between males and females could be a confounding factor in our study, as they may influence EIB and susceptibility to AD. Future research should consider hormonal information when investigating sex differences in EIB and its relation to neurodegenerative diseases (in particular, evaluating female EIB progression separated by pre- and post-menopause).

Last, our findings contribute to the understanding of how EIB is involved in neurodevelopmental disorders and neurodegenerative diseases (such as autism spectrum disorder, schizophrenia, attention deficit/hyperactivity disorder, and AD) and how sex differences in EIB may be leveraged to inform therapeutic intervention and clinical endpoints. As a therapeutic target, transcranial direct current stimulation (tDCS) has emerged as a promising therapy for rehabilitating neurodevelopmental disorders such as autism, schizophrenia, attention deficit/hyperactivity disorder, and even epilepsy [80, 91–93]. The mechanism behind tDCS's effects is the modulation of excitatory and inhibitory activity, making it a valuable tool for restoring excitation-inhibition balance. Clinical studies have demonstrated that tDCS therapy is well-tolerated by patients and appears to improve behavior and cognitive functions. Further, AD patients present an increased prevalence of epilepsy, with neural hypersynchrony and aberrant oscillatory activity contributing to cognitive deterioration [94–96]. Levetiracetam (LEV) has shown effectiveness in reducing epileptiform activity in AD patients, correlating with improved cognitive performance [97, 98]. Ongoing clinical trials are assessing LEV's effectiveness in AD patients without epilepsy, indicating potential future clinical applications of our hybrid connectome and EIB in the context of epilepsy and AD [99].

Our results, along with the growing body of evidence conceptualizing AD neuropathology in terms of an imbalance of excitation and inhibition suggests that females early in the disease progression (particularly those with the *APOE* $\epsilon 4$ genotype) may be more responsive to tDCS or low doses of anticonvulsants. The hybrid connectome (rs-SC) framework used to infer excitation-inhibition balance at an individual level, may be a step towards an MRI-based

biomarker to identify hyperexcitation-induced neurodegeneration before traditional indicators of AD arise and potentially evaluate therapeutic interventions and clinical endpoints.

ACKNOWLEDGMENTS

The magnetic resonance imaging and neuropsychological tests data that support the findings of this study are available in ["OASIS-3"] with the identifier(s) (<https://doi.org/10.1101/2019.12.13.19014902>) [39]. OASIS-3: Longitudinal Multimodal Neuroimaging: Principal Investigators: T. Benzinger, D. Marcus, J. Morris; NIH P30 AG066444, P50 AG00561, P30 NS09857781, P01 AG026276, P01 AG003991, R01 AG043434, UL1 TR000448, R01 EB009352. AV-45 doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly.

OASIS-3 data are openly available to the scientific community at <https://www.oasisbrains.org>. Prior to accessing the data, users are required to agree to the OASIS data use terms (DUT), which follow the creative commons attribution 4.0 license.

FUNDING

This study was partially supported by the National Institutes of Health (R01AG071243, R01MH125928, and U01AG068057) and National Science Foundation (IIS 2045848).

CONFLICT OF INTEREST

The authors have no conflict of interest to report.

DATA AVAILABILITY

The data supporting the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

SUPPLEMENTARY MATERIAL

The supplementary material is available in the electronic version of this article: <https://dx.doi.org/10.3233/JAD-230035>.

REFERENCES

- [1] Kinouchi O, Copelli M (2006) Optimal dynamical range of excitable networks at criticality. *Nat Phys* **2**, 348-351.
- [2] Shew WL, Yang H, Yu S, Roy R, Plenz D (2011) Information capacity and transmission are maximized in balanced cortical networks with neuronal avalanches. *J Neurosci* **31**, 55-63.
- [3] Zullo JM, Drake D, Aron L, O'Hern P, Dhamne SC, Davidsohn N, Mao C-A, Klein WH, Rotenberg A, Bennett DA, Church GM, Colaiácovo MP, Yankner BA (2019) Regulation of lifespan by neural excitation and REST. *Nature* **574**, 359-364.
- [4] Perica MI, Calabro FJ, Larsen B, Foran W, Yushmanov VE, Hetherington H, Tervo-Clemmens B, Moon C-H, Luna B (2022) Development of frontal GABA and glutamate supports excitation/inhibition balance from adolescence into adulthood. *Prog Neurobiol* **219**, 102370.
- [5] Gallagher M, Okonkwo OC, Resnick SM, Jagust WJ, Benzinger TLS, Rapp PR (2019) What are the threats to successful brain and cognitive aging? *Neurobiol Aging* **83**, 130-134.
- [6] Nelson SB, Valakh V (2015) Excitatory/inhibitory balance and circuit homeostasis in autism spectrum disorders. *Neuron* **87**, 684-698.
- [7] Rubenstein JLR, Merzenich MM (2003) Model of autism: Increased ratio of excitation/inhibition in key neural systems. *Genes Brain Behav* **2**, 255-267.
- [8] Fernandez F, Garner CC (2007) Over-inhibition: A model for developmental intellectual disability. *Trends Neurosci* **30**, 497-503.
- [9] Burke SN, Barnes CA (2006) Neural plasticity in the ageing brain. *Nat Rev Neurosci* **7**, 30-40.
- [10] Li J, Park E, Zhong L, Chen L (2019) Homeostatic synaptic plasticity as a metaplasticity mechanism – a molecular and cellular perspective. *Curr Opin Neurobiol* **54**, 44-53.
- [11] Morrison JH, Baxter MG (2012) The ageing cortical synapse: Hallmarks and implications for cognitive decline. *Nat Rev Neurosci* **13**, 240-250.
- [12] Fortel I, Butler M, Korthauer LE, Zhan L, Ajilore O, Sidiropoulos A, Wu Y, Driscoll I, Schonfeld D, Leow A (2022) Inferring excitation-inhibition dynamics using a maximum entropy model unifying brain structure and function. *Netw Neurosci* **6**, 420-444.
- [13] Reichl LE (1998) *A Modern Course in Statistical Physics, 2nd Edition*. John Wiley & Sons, Inc.
- [14] Deco G, Jirsa VK, Robinson PA, Breakspear M, Friston K (2008) The dynamic brain: From spiking neurons to neural masses and cortical fields. *PLoS Comput Biol* **4**, e1000092.
- [15] Kadirvelu B, Hayashi Y, Nasuto SJ (2017) Inferring structural connectivity using Ising couplings in models of neuronal networks. *Sci Rep* **7**, 8156.
- [16] Ostojic S, Brunel N (2011) From spiking neuron models to linear-nonlinear models. *PLoS Comput Biol* **7**, e1001056.
- [17] Tkačik G, Marre O, Mora T, Amodei D, II MJB, Bialek W (2013) The simplest maximum entropy model for collective behavior in a neural network. *J Stat Mech* **2013**, P03011.
- [18] Ezaki T, Watanabe T, Ohzeki M, Masuda N (2017) Energy landscape analysis of neuroimaging data. *Philos Trans A Math Phys Eng Sci* **375**, 20160287.
- [19] Marinazzo D, Pellicoro M, Wu G, Angelini L, Cortés JM, Stramaglia S (2014) Information transfer and criticality in the Ising model on the human connectome. *PLoS One* **9**, e93616.
- [20] Nghiem T-A, Telenczuk B, Marre O, Destexhe A, Ferrari U (2018) Maximum-entropy models reveal the excitatory and inhibitory correlation structures in cortical neuronal activity. *Phys Rev E* **98**, 012402.
- [21] Niu W, Huang X, Xu K, Jiang T, Yu S (2019) Pairwise interactions among brain regions organize large-scale functional connectivity during execution of various tasks. *Neuroscience* **412**, 190-206.
- [22] Nuzzi D, Pellicoro M, Angelini L, Marinazzo D, Stramaglia S (2020) Synergistic information in a dynamical model implemented on the human structural connectome reveals spatially distinct associations with age. *Netw Neurosci* **4**, 910-924.
- [23] Schneidman E, Berry MJ, Segev R, Bialek W (2006) Weak pairwise correlations imply strongly correlated network states in a neural population. *Nature* **440**, 1007-1012.
- [24] Roudi Y, Tyrcha J, Hertz J (2009) Ising model for neural data: Model quality and approximate methods for extracting functional connectivity. *Phys Rev E* **79**, 051915.
- [25] Shlens J, Field GD, Gauthier JL, Grivich MI, Petrusca D, Sher A, Litke AM, Chichilnisky EJ (2006) The structure of multi-neuron firing patterns in primate retina. *J Neurosci* **26**, 8254-8266.
- [26] Ashourvan A, Gu S, Mattar MG, Vettel JM, Bassett DS (2017) The energy landscape underpinning module dynamics in the human brain connectome. *Neuroimage* **157**, 364-380.
- [27] Cocco S, Monasson R, Posani L, Tavoni G (2017) Functional networks from inverse modeling of neural population activity. *Curr Opin Syst Biol* **3**, 103-110.
- [28] Ezaki T, Fonseca dos Reis E, Watanabe T, Sakaki M, Masuda N (2020) Closer to critical resting-state neural dynamics in individuals with higher fluid intelligence. *Commun Biol* **3**, 52.
- [29] Watanabe T, Hirose S, Wada H, Imai Y, Machida T, Shirouzu I, Konishi S, Miyashita Y, Masuda N (2013) A pairwise maximum entropy model accurately describes resting-state human brain networks. *Nat Commun* **4**, 1370.
- [30] Zanoci C, Dehghani N, Tegmark M (2019) Ensemble inhibition and excitation in the human cortex: An Ising-model analysis with uncertainties. *Phys Rev E* **99**, 032408.
- [31] Altmann A, Tian L, Henderson VW, Greicius MD (2014) Sex modifies the APOE-related risk of developing Alzheimer disease. *Ann Neurol* **75**, 563-573.
- [32] Liu M, Paranjpe MD, Zhou X, Duy PQ, Goyal MS, Benzinger TLS, Lu J, Wang R, Zhou Y (2019) Sex modulates the ApoE e4 effect on brain tau deposition measured by 18F-AV-1451 PET in individuals with mild cognitive impairment. *Theranostics* **9**, 4959-4970.
- [33] Valencia-Olvera AC, Maldonado Weng J, Christensen A, LaDu MJ, Pike CJ (2023) Role of estrogen in women's Alzheimer's disease risk as modified by APOE. *J Neuroendocrinol* **35**, e13209.
- [34] Scheyer O, Rahman A, Hristov H, Berkowitz C, Isaacson RS, Diaz Brinton R, Mosconi L (2018) Female sex and Alzheimer's risk: The menopause connection. *J Prev Alzheimers Dis* **5**, 225-230.
- [35] Woitowich NC, Woodruff TK (2019) Opinion: Research community needs to better appreciate the value of sex-based research. *Proc Natl Acad Sci U S A* **116**, 7154-7156.
- [36] Veitch DP, Weiner MW, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ (2019) Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights

- from the Alzheimer's Disease Neuroimaging Initiative. *Alzheimers Dement* **15**, 106-152.
- [37] LaMontagne PJ, Benzinger TLS, Morris JC, Keefe S, Hornbeck R, Xiong C, Grant E, Hassenstab J, Moulder K, Vlassenko A, Raichle ME, Cruchaga C, Marcus D (2019) OASIS-3: Longitudinal neuroimaging, clinical, and cognitive dataset for normal aging and Alzheimer disease. *medRxiv*, 2019.12.13.19014902.
- [38] Fields JA, Ferman TJ, Boeve BF, Smith GE (2011) Neuropsychological assessment of patients with dementing illness. *Nat Rev Neurol* **7**, 677-687.
- [39] LaMontagne PJ, Benzinger TLS, Morris JC, Keefe S, Hornbeck R, Xiong C, Grant E, Hassenstab J, Moulder K, Vlassenko AG, Raichle ME, Cruchaga C, Marcus D (2019) OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease. *medRxiv*, 2019.12.13.19014902; doi: <https://doi.org/10.1101/2019.12.13.19014902>.
- [40] Raber J, Huang Y, Ashford JW (2004) ApoE genotype accounts for the vast majority of AD risk and AD pathology. *Neurobiol Aging* **25**, 641-650.
- [41] Uddin MdS, Kabir MdT, Al Mamun A, Abdel-Daim MM, Barreto GE, Ashraf GM (2019) APOE and Alzheimer's disease: Evidence mounts that targeting APOE4 may combat Alzheimer's pathogenesis. *Mol Neurobiol* **56**, 2450-2465.
- [42] Sienski G, Narayan P, Bonner JM, Kory N, Boland S, Arczewska AA, Ralvenius WT, Akay L, Lockshin E, He L, Milo B, Graziosi A, Baru V, Lewis CA, Kellis M, Sabatini DM, Tsai L-H, Lindquist S (2021) APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia. *Sci Transl Med* **13**, eaaz4564.
- [43] Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* **261**, 921-923.
- [44] Liu C-C, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. *Nat Rev Neurol* **9**, 106-118.
- [45] Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, Duijn CM van (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis. *JAMA* **278**, 1349-1356.
- [46] Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ, Chen Y, Su Y, Myers AJ, Hardy J, Paul Vonsattel J, Younkin SG, Bennett DA, De Jager PL, Larson EB, Crane PK, Keene CD, Kamboh MI, Kofler JK, Duque L, Gilbert JR, Gwirtsman HE, Buxbaum JD, Dickson DW, Frosch MP, Ghetti BF, Lunetta KL, Wang L-S, Hyman BT, Kukull WA, Foroud T, Haines JL, Mayeux RP, Pericak-Vance MA, Schneider JA, Trojanowski JQ, Farrer LA, Schellenberg GD, Beecham GW, Montine TJ, Jun GR, Alzheimer's Disease Genetics Consortium (2020) Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study. *Nat Commun* **11**, 667.
- [47] Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* **12**, 189-198.
- [48] Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO (1982) Development and validation of a geriatric depression screening scale: A preliminary report. *J Psychiatr Res* **17**, 37-49.
- [49] Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, Wu J, Hubbard JL, Koepsell TD, Morris JC, Kukull WA, NIA Alzheimer's Disease Centers (2007) The National Alzheimer's Coordinating Center (NACC) database: The Uniform Data Set. *Alzheimer Dis Assoc Disord* **21**, 249-258.
- [50] Morris JC, Weintraub S, Chui HC, Cummings J, DeCarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, Kukull WA (2006) The Uniform Data Set (UDS): Clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. *Alzheimer Dis Assoc Disord* **20**, 210-216.
- [51] Fillenbaum GG, Peterson B, Morris JC (1996) Estimating the validity of the Clinical Dementia Rating Scale: The CERAD experience. *Aging Clin Exp Res* **8**, 379-385.
- [52] Morris JC (1997) Clinical dementia rating: A reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. *Int Psychogeriatr* **9**(Suppl 1), 173-176; discussion 177-178.
- [53] Marcus DS, Wang TH, Parker J, Csernansky JG, Morris JC, Buckner RL (2007) Open Access Series of Imaging Studies (OASIS): Cross-sectional MRI data in young, middle aged, nondemented, and demented older adults. *J Cogn Neurosci* **19**, 1498-1507.
- [54] Morris JC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. *Neurology* **43**, 2412.2-2412.a.
- [55] Weintraub S, Salmon D, Mercaldo N, Ferris S, Graff-Radford NR, Chui H, Cummings J, DeCarli C, Foster NL, Galasko D, Peskind E, Dietrich W, Beekly DL, Kukull WA, Morris JC (2009) The Alzheimer's Disease Centers' Uniform Data Set (UDS): The neuropsychologic test battery. *Alzheimer Dis Assoc Disord* **23**, 91-101.
- [56] Fortel I, Butler M, Korthauer LE, Zhan L, Ajilore O, Driscoll I, Sidiropoulos A, Zhang Y, Guo L, Huang H, Schonfeld D, Leow A (2019) Brain dynamics through the lens of statistical mechanics by unifying structure and function. In *Medical Image Computing and Computer Assisted Intervention – MICCAI 2019*, Shen D, Liu T, Peters TM, Staib LH, Essert C, Zhou S, Yap P-T, Khan A, eds. Springer International Publishing, Cham, pp. 503-511.
- [57] Nghiem T-A, Marre O, Destexhe A, Ferrari U (2017) Pairwise ising model analysis of human cortical neuron recordings. In *Geometric Science of Information*, Nielsen F, Barbaresco F, eds. Springer International Publishing, Cham, pp. 257-264.
- [58] Koenig LN, LaMontagne P, Glasser MF, Bateman R, Holtzman D, Yakushev I, Chhatwal J, Day GS, Jack C, Mummery C, Perrin RJ, Gordon BA, Morris JC, Shimony JS, Benzinger TLS (2022) Regional age-related atrophy after screening for preclinical Alzheimer disease. *Neurobiol Aging* **109**, 43-51.
- [59] Fortel I, Korthauer LE, Morrissey Z, Zhan L, Ajilore O, Wolfson O, Driscoll I, Schonfeld D, Leow A (2020) Connectome signatures of hyperexcitation in cognitively intact middle-aged female APOE-ε4 carriers. *Cereb Cortex* **30**, 6350-6362.
- [60] Korthauer LE, Zhan L, Ajilore O, Leow A, Driscoll I (2018) Disrupted topology of the resting state structural connectome in middle-aged APOE ε4 carriers. *Neuroimage* **178**, 295-305.
- [61] Korthauer L (2018) Structural and functional brain connectivity in middle-aged carriers of risk alleles for Alzheimer's disease. *Theses and Dissertations*, 1849. <https://dc.uwm.edu/etd/1849>

- [62] Lopatina OL, Malinovskaya NA, Komleva YK, Gorina YV, Shuvaev AN, Olovyannikova RY, Belozor OS, Belova OA, Higashida H, Salmira AB (2019) Excitation/inhibition imbalance and impaired neurogenesis in neurodevelopmental and neurodegenerative disorders. *Rev Neurosci* **30**, 807-820.
- [63] Legon W, Punzell S, Dowlati E, Adams SE, Stiles AB, Moran RJ (2016) Altered prefrontal excitation/inhibition balance and prefrontal output: Markers of aging in human memory networks. *Cereb Cortex* **26**, 4315-4326.
- [64] Aron L, Zullo J, Yankner BA (2022) The adaptive aging brain. *Curr Opin Neurobiol* **72**, 91-100.
- [65] Kaczurkin AN, Raznahan A, Satterthwaite TD (2019) Sex differences in the developing brain: Insights from multimodal neuroimaging. *Neuropsychopharmacol* **44**, 71-85.
- [66] Bi D, Wen L, Wu Z, Shen Y (2020) GABAergic dysfunction in excitatory and inhibitory (E/I) imbalance drives the pathogenesis of Alzheimer's disease. *Alzheimers Dement* **16**, 1312-1329.
- [67] Gomez-Ramirez J, Wu J (2014) Network-based biomarkers in Alzheimer's disease: Review and future directions. *Front Aging Neurosci* **6**, 12.
- [68] Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD (2009) Neurodegenerative diseases target large-scale human brain networks. *Neuron* **62**, 42-52.
- [69] Theriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Savard M, Chamoun M, Thomas E, Kang MS, Lussier F, Tissot C, Soucy J-P, Massarweh G, Rej S, Saha-Chaudhuri P, Poirier J, Gauthier S, Rosa-Neto P (2021) APOE ϵ 4 potentiates the relationship between amyloid- β and tau pathologies. *Mol Psychiatry* **26**, 5977-5988.
- [70] Busche MA, Hyman BT (2020) Synergy between amyloid- β and tau in Alzheimer's disease. *Nat Neurosci* **23**, 1183-1193.
- [71] Targa Dias Anastacio H, Matosin N, Ooi L (2022) Neuronal hyperexcitability in Alzheimer's disease: What are the drivers behind this aberrant phenotype? *Transl Psychiatry* **12**, 257.
- [72] Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee J-M, Holtzman DM (2011) Neuronal activity regulates the regional vulnerability to amyloid- β deposition. *Nat Neurosci* **14**, 750-756.
- [73] Cirrito JR, Kang J-E, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM (2008) Endocytosis is required for synaptic activity-dependent release of amyloid- β *in vivo*. *Neuron* **58**, 42-51.
- [74] Rodriguez GA, Barrett GM, Duff KE, Hussaini SA (2020) Chemogenetic attenuation of neuronal activity in the entorhinal cortex reduces A β and tau pathology in the hippocampus. *PLoS Biol* **18**, e3000851.
- [75] Yan S, Zheng C, Paranjpe MD, Li Y, Li W, Wang X, Benzinger TLS, Lu J, Zhou Y (2021) Sex modifies APOE ϵ 4 dose effect on brain tau deposition in cognitively impaired individuals. *Brain* **144**, 3201-3211.
- [76] Yin X, Wang Y, Li J, Guo ZV (2022) Lateralization of short-term memory in the frontal cortex. *Cell Rep* **40**, 111190.
- [77] Ries SK, Dronkers NF, Knight RT (2016) Choosing words: Left hemisphere, right hemisphere, or both? Perspective on the lateralization of word retrieval. *Ann N Y Acad Sci* **1369**, 111-131.
- [78] Ashendorf L, Jefferson AL, O'Connor MK, Chaisson C, Green RC, Stern RA (2008) Trail Making Test errors in normal aging, mild cognitive impairment, and dementia. *Arch Clin Neuropsychol* **23**, 129-137.
- [79] Cotelli M, Calabria M, Manenti R, Rosini S, Zanetti O, Cappa SF, Miniussi C (2011) Improved language performance in Alzheimer disease following brain stimulation. *J Neurol Neurosurg Psychiatry* **82**, 794-797.
- [80] Im JJ, Jeong H, Bikson M, Woods AJ, Unal G, Oh JK, Na S, Park J-S, Knotkova H, Song I-U, Chung Y-A (2019) Effects of 6-month at-home transcranial direct current stimulation on cognition and cerebral glucose metabolism in Alzheimer's disease. *Brain Stimul* **12**, 1222-1228.
- [81] Mather M, Harley CW (2016) The locus coeruleus: Essential for maintaining cognitive function and the aging brain. *Trends Cogn Sci* **20**, 214-226.
- [82] Lu K, Nicholas JM, Pertzov Y, Grogan J, Husain M, Pavisic IM, James S-N, Parker TD, Lane CA, Keshavan A, Keuss SE, Buchanan SM, Murray-Smith H, Cash DM, Malone IB, Coath W, Wong A, Henley SMD, Crutch SJ, Fox NC, Richards M, Schott JM (2020) APOE- ϵ 4 carriers have superior recall on the 'What was where?' visual short-term memory binding test at age 70, despite a detrimental effect of β -amyloid. *Alzheimers Dement* **16**, e041090.
- [83] Zokaei N, Grogan J, Fallon SJ, Slavkova E, Hadida J, Manohar S, Nobre AC, Husain M (2020) Short-term memory advantage for brief durations in human APOE ϵ 4 carriers. *Sci Rep* **10**, 9503.
- [84] Zokaei N, Čepukaitytė G, Board AG, Mackay CE, Husain M, Nobre AC (2019) Dissociable effects of the apolipoprotein-E (APOE) gene on short- and long-term memories. *Neurobiol Aging* **73**, 115-122.
- [85] Mortamais M, Ash JA, Harrison J, Kaye J, Kramer J, Randolph C, Pose C, Albala B, Ropacki M, Ritchie CW, Ritchie K (2017) Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility. *Alzheimers Dement* **13**, 468-492.
- [86] Jack CR Jr, Wiste HJ, Therneau TM, Weigand SD, Knopman DS, Mielke MM, Lowe VJ, Vemuri P, Machulda MM, Schwarz CG, Gunter JL, Senjem ML, Graff-Radford J, Jones DT, Roberts RO, Rocca WA, Petersen RC (2019) Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. *JAMA* **321**, 2316-2325.
- [87] Arenaza-Urquijo EM, Vemuri P (2018) Resistance vs resilience to Alzheimer disease: Clarifying terminology for preclinical studies. *Neurology* **90**, 695-703.
- [88] Habeck C, Razlighi Q, Gazes Y, Barulli D, Steffener J, Stern Y (2017) Cognitive reserve and brain maintenance: Orthogonal concepts in theory and practice. *Cereb Cortex* **27**, 3962-3969.
- [89] Vemuri P, Weigand SD, Przybelski SA, Knopman DS, Smith GE, Trojanowski JQ, Shaw LM, Decarli CS, Carmichael O, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CR Jr, on behalf of the Alzheimer's Disease Neuroimaging Initiative (2011) Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. *Brain* **134**, 1479-1492.
- [90] Hohman TJ, McLaren DG, Mormino EC, Gifford KA, Libon DJ, Jefferson AL, Alzheimer's Disease Neuroimaging Initiative (2016) Asymptomatic Alzheimer disease: Defining resilience. *Neurology* **87**, 2443-2450.
- [91] Sousa B, Martins J, Castelo-Branco M, Gonçalves J (2022) Transcranial direct current stimulation as an approach to mitigate neurodevelopmental disorders affecting excitation/inhibition balance: Focus on autism spectrum disorder, schizophrenia, and attention deficit/hyperactivity disorder. *J Clin Med* **11**, 2839.

- [92] Ren S-Q, Yao W, Yan J-Z, Jin C, Yin J-J, Yuan J, Yu S, Cheng Z (2018) Amyloid β causes excitation/inhibition imbalance through dopamine receptor 1-dependent disruption of fast-spiking GABAergic input in anterior cingulate cortex. *Sci Rep* **8**, 302.
- [93] Yang D, Wang Q, Xu C, Fang F, Fan J, Li L, Du Q, Zhang R, Wang Y, Lin Y, Huang Z, Wang H, Chen C, Xu Q, Wang Y, Zhang Y, Zhang Z, Zhao X, Zhao X, Li T, Liu C, Niu Y, Zhou Q, Zhou Q, Duan Y, Liu X, Yu T, Xue Q, Li J, Dai X, Han J, Ren C, Xu H, Li N, Zhang J, Xu N, Yang K, Wang Y (2020) Transcranial direct current stimulation reduces seizure frequency in patients with refractory focal epilepsy: A randomized, double-blind, sham-controlled, and three-arm parallel multicenter study. *Brain Stimul* **13**, 109-116.
- [94] Horváth A, Szűcs A, Hidasi Z, Csukly G, Barcs G, Kamondi A (2018) Prevalence, semiology, and risk factors of epilepsy in Alzheimer's disease: An ambulatory EEG study. *J Alzheimers Dis* **63**, 1045-1054.
- [95] Vossel KA, Tartaglia MC, Nygaard HB, Zeman AZ, Miller BL (2017) Epileptic activity in Alzheimer's disease: Causes and clinical relevance. *Lancet Neurol* **16**, 311-322.
- [96] Aboud O, Mrak RE, Boop FA, Griffin WST (2013) Epilepsy: Neuroinflammation, neurodegeneration, and APOE genotype. *Acta Neuropathol Commun* **1**, 41.
- [97] Press DZ, Musaeus CS, Zhao L, Breton J, Shafi MM, Dai W, Alsop DC (2023) Levetiracetam increases hippocampal blood flow in Alzheimer's disease as measured by arterial spin labelling MRI. *J Alzheimers Dis* **93**, 939-948.
- [98] Vossel K, Ranasinghe KG, Beagle AJ, La A, Ah Pook K, Castro M, Mizuiri D, Honma SM, Venkateswaran N, Koestler M, Zhang W, Mucke L, Howell MJ, Possin KL, Kramer JH, Boxer AL, Miller BL, Nagarajan SS, Kirsch HE (2021) Effect of levetiracetam on cognition in patients with Alzheimer disease with and without epileptiform activity: A randomized clinical trial. *JAMA Neurol* **78**, 1345-1354.
- [99] Sen A, Akinola M, Tai XY, Symmonds M, Davis Jones G, Mura S, Galloway J, Hallam A, Chan JYC, Koychev I, Butler C, Geddes J, Van Der Putt R, Thompson S, Manohar SG, Frangou E, Love S, McShane R, Husain M (2021) An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): A double-blind, placebo-controlled, randomised crossover proof of concept study. *Trials* **22**, 508.